Episode Details

Omega Fund Management sold over four hundred eleven thousand shares of Alumis, earning ten million three hundred thousand dollars, indicating a portfolio rebalancing. Alumis stock surged three hundred twenty-seven percent earlier this year, and the company is pushing forward with clinical trials for autoimmune treatments. They aim to submit their lead drug candidate to the FDA by Q4 2026. Despite a net loss of ninety-three million one hundred thousand dollars, Alumis has over five hundred sixty-nine million dollars in the bank. The companys success hinges on turning clinical momentum into a commercial success, with upcoming lupus trial results as the next key indicator.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/5e5157d10c2953b1